about
TRIM24 links a non-canonical histone signature to breast cancerSapacitabine for cancerUCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes.Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.Phase I trial of nelarabine in indolent leukemias.Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyIntracellular succinylation of 8-chloroadenosine and its effect on fumarate levels.Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemiaPolyadenylation inhibition by the triphosphates of deoxyadenosine analogues.Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.Clofarabine in leukemia.Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemiaPhase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignanciesEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Cellular and clinical pharmacology of fludarabine.Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemiaIntra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancerNew nucleoside analogues in clinical development.DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor.Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemiaA proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removalPharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trialMdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemiaPhase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.miRNAs and their potential for use against cancer and other diseases.microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survivalATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia
P50
Q24317243-CE1F6B77-F8ED-40C8-9E2E-C369F34354C2Q27024675-33FD5D92-A882-4C83-A945-1A29BCDFD4D6Q33185362-13C0AA00-1CB5-4797-B685-CBD970838478Q33315217-92A582E6-E66B-4FEA-8AC7-6F09BBE7613DQ33366921-D9821491-5CE9-4C3B-982A-8906E52B2CE5Q33378808-53CEC20F-091F-4E9C-B484-270C62B5EAF7Q33403865-370960F6-1233-4E98-BB9B-D9813388CFB8Q33707009-2DF9844B-4F32-4CB6-A2BB-E5318118DE69Q33721114-DE5A2D68-CBC5-4C22-A45C-7043464EBF1EQ33721126-5CEADF5B-C144-490E-BC6F-D2250ADFD69FQ34091061-67649899-F9EB-4880-9D72-41D51AB762AFQ34150263-72F1044E-545E-4B83-884F-C03C5AFDD6A8Q34163011-5D0F6CC6-14A6-4D72-908B-817BC77201BCQ34269186-27F2E172-A2F9-43A1-BD5E-F2FE308BCD82Q34279005-F947371A-CD14-425F-B027-58104184F7EBQ34367804-B60C0FB5-F918-44FC-B03D-28DA279686EDQ34402999-2D37F5A0-2E92-40BA-A55A-0D89E0F9A9C3Q34508322-35D55801-0BCD-4515-AB92-04B3612EE2D5Q34558562-26357C66-D721-459D-A264-C5E5A28B76A3Q34568840-10131781-E7B8-4C8F-9239-70DEB8919852Q34701798-2A5FA97B-7E0E-4032-995A-2F603F2B6579Q35110375-B70243CF-F151-4B94-88B5-C2E9E07D50EDQ35122824-2F988292-7BCD-4377-B6EC-CE9DA105C117Q35791336-EFB02710-C058-4A00-8334-F601743F2F64Q35848202-B5CD15B2-2831-44AC-A925-F207716B1B48Q35848241-B306DC77-56C4-46BF-B296-314B47DFF154Q35848805-B2F1D2E7-7186-44B7-9BD1-9A14CEC34A35Q35849547-F508FB0B-9E69-4DCD-9179-880AEBE261FEQ35849887-B55E854B-07A2-4796-BEDF-4735D3BBC76CQ35924564-0AD28B42-4872-4777-B76C-1FD75B611B56Q36085774-87897B74-2220-4E0E-ACA7-414F7D7E09C7Q36119450-675EF0EE-00DD-41F6-9A11-25B79CAE1545Q36597026-67909E8A-6FF3-41E9-849A-142BBF551C58Q36843744-2E3977A3-0365-42AC-BADF-B3FCDC4CBAB3Q36913236-8D5DDBA7-861C-46D0-8E96-421D681ACB29Q36915178-825E2CBA-85B7-4A15-8F43-3490C1E21537Q36967297-B7875A9D-DAE1-40D1-A6DC-3B70D1AEAFEDQ37027816-69E25A57-822A-4B09-A522-25B9A03D0481Q37074086-F039C630-70D5-44DD-B9C9-FB0BC54D6EE3Q37100102-B50C9F0C-169F-44F9-8A63-8D76DBFC2F8D
P50
name
William Plunkett
@ast
William Plunkett
@en
William Plunkett
@es
William Plunkett
@nl
type
label
William Plunkett
@ast
William Plunkett
@en
William Plunkett
@es
William Plunkett
@nl
prefLabel
William Plunkett
@ast
William Plunkett
@en
William Plunkett
@es
William Plunkett
@nl